Formycon AG (0W4N.L)
EUR 53.2
(0.95%)
EUR 53.2
(0.95%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.45 Million EUR | -93.79% |
| 2022 | 39.48 Million EUR | 299.98% |
| 2021 | -19.74 Million EUR | 46.67% |
| 2020 | -37.02 Million EUR | -67.43% |
| 2019 | -22.11 Million EUR | -201.46% |
| 2018 | -7.33 Million EUR | -62.88% |
| 2017 | -4.5 Million EUR | -50.4% |
| 2016 | -2.99 Million EUR | -381.09% |
| 2015 | -622.48 Thousand EUR | -115.47% |
| 2014 | -288.89 Thousand EUR | 67.88% |
| 2013 | -899.31 Thousand EUR | -322.59% |
| 2012 | -212.8 Thousand EUR | -173.89% |
| 2011 | 288 Thousand EUR | 121.01% |
| 2010 | -1.37 Million EUR | -19485.04% |
| 2009 | -7000.00 EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -29.75 Million EUR | 0.0% |
| 2023 Q2 | -28.05 Million EUR | 0.0% |
| 2023 FY | 2.45 Million EUR | -93.79% |
| 2023 Q4 | 2.45 Million EUR | 0.0% |
| 2022 Q2 | -9.21 Million EUR | 0.0% |
| 2022 FY | 39.48 Million EUR | 299.98% |
| 2022 Q4 | 39.48 Million EUR | 0.0% |
| 2021 FY | -19.74 Million EUR | 46.67% |
| 2021 Q4 | -20.62 Million EUR | 0.0% |
| 2021 Q2 | -33.47 Million EUR | 0.0% |
| 2020 FY | -37.02 Million EUR | -67.43% |
| 2020 Q4 | -42 Million EUR | 0.0% |
| 2020 Q2 | -19.99 Million EUR | 0.0% |
| 2019 FY | -22.11 Million EUR | -201.46% |
| 2019 Q4 | -22.11 Million EUR | 0.0% |
| 2019 Q2 | -7.48 Million EUR | 0.0% |
| 2018 FY | -7.33 Million EUR | -62.88% |
| 2018 Q2 | -4.84 Million EUR | 0.0% |
| 2018 Q4 | -7.33 Million EUR | 0.0% |
| 2017 Q4 | -4.5 Million EUR | 0.0% |
| 2017 FY | -4.5 Million EUR | -50.4% |
| 2017 Q2 | -3.44 Million EUR | 0.0% |
| 2016 FY | -2.99 Million EUR | -381.09% |
| 2016 Q4 | -2.99 Million EUR | 0.0% |
| 2016 Q2 | -5.81 Million EUR | 0.0% |
| 2015 Q4 | -622.48 Thousand EUR | 0.0% |
| 2015 FY | -622.48 Thousand EUR | -115.47% |
| 2015 Q2 | -4.72 Million EUR | 0.0% |
| 2014 Q2 | -552.52 Thousand EUR | 0.0% |
| 2014 FY | -288.89 Thousand EUR | 67.88% |
| 2014 Q4 | -288.89 Thousand EUR | 0.0% |
| 2013 Q4 | -899.31 Thousand EUR | 0.0% |
| 2013 FY | -899.31 Thousand EUR | -322.59% |
| 2013 Q2 | -4.63 Million EUR | 0.0% |
| 2012 Q4 | -212.8 Thousand EUR | 0.0% |
| 2012 Q2 | 1.19 Million EUR | 0.0% |
| 2012 FY | -212.8 Thousand EUR | -173.89% |
| 2011 FY | 288 Thousand EUR | 121.01% |
| 2010 FY | -1.37 Million EUR | -19485.04% |
| 2009 FY | -7000.00 EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Boiron SA | -60.34 Million EUR | 104.062% |
| Laboratorios Farmaceuticos Rovi, S.A. | 21.31 Million EUR | 88.5% |
| Vetoquinol SA | -129.83 Million EUR | 101.888% |
| Valneva SE | 82.73 Million EUR | 97.038% |
| AB Science S.A. | 13.03 Million EUR | 81.197% |
| Nanobiotix S.A. | -29.8 Million EUR | 108.225% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | 991.273% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 113.231% |
| BioSenic S.A. | 28.04 Million EUR | 91.26% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 101.247% |